|
시장보고서
상품코드
2039072
BRAF 키나아제 저해제 시장 : 약제별, 적응증별, 유통 채널별, 지역별BRAF Kinase Inhibitors Market, By Drug, By Indication, By Distribution Channel, By Geography |
||||||
BRAF 키나아제 저해제 시장은 2026년에 21억 2,000만 달러로 추계되고 있으며, 2033년까지 35억 2,000만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 8.3%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 21억 2,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 8.30% | 2033년 시장 규모 예측 : | 35억 2,000만 달러 |
BRAF는 세포의 증식과 신호전달을 조절하는 역할을 하는 키나아제 효소입니다. 흑색종이나 대장암 등 일부 암에서는 돌연변이(변이)된 형태로 나타나기도 합니다. 변이된 BRAF 키나아제 단백질을 억제함으로써 암세포의 증식을 억제할 수 있는 가능성이 있습니다. 일부 BRAF 키나아제 억제제는 암 치료에 사용되고 있습니다. 흑색종의 약 50%에서 BRAF의 활성화 돌연변이(90% 이상이 V600E)가 발견됩니다. BRAFV600E는 흑색종 발생의 기저에 있는 다양한 메커니즘에 관여하는 것으로 생각되며, 그 중 많은 부분이 다운스트림 MEK/ERK 이펙터의 제어할 수 없는 활성화에 기인하는 것으로 알려져 있습니다. 두 가지 화합물(베믈라페닙과 다브라페닙)은 전이성 및 절제 불가능한 BRAF 변이형 흑색종 치료제로 미국 식품의약국(FDA)의 승인을 받았습니다.
시장 역학
BRAF 키나아제 억제제 시장의 주요 기업은 특허 취득에 집중하고 있으며, 이는 신흥 국가 BRAF 키나아제 억제제 제조업체들에게 더 많은 기회를 제공할 것으로 예상됩니다. 예를 들어 2016년 9월 노바티스 인터내셔널 AG는 피부암(흑색종) 치료제 '타핀러'에 대한 인도 특허를 취득했습니다. 이 약은 생존율이 낮고 가장 심각하고 생명을 위협하는 피부암의 일종인 전이성 흑색종 치료에 사용됩니다.
그러나 BRAF 키나아제 억제제 시장이 해결해야 할 과제 중 하나는 환자의 복약 순응도입니다. BRAF 키나아제 억제제의 고비용으로 인해 환자들은 원래의 치료법에서 다른 암 치료법으로 전환하고 있습니다. 암 치료에 사용할 수 있는 대체요법의 존재는 가까운 장래에 BRAF 키나아제 억제제 시장의 성장을 저해할 것으로 예상됩니다. 예를 들어 전이성 암의 경우 화학요법이나 호르몬 요법 등 전신 암세포에 도달하기 위해 경구 또는 정맥으로 투여하는 전신요법이나 약물을 필요로 합니다. 다른 치료법으로는 면역요법, 방사선 치료, 수술 또는 이들의 조합 등을 들 수 있습니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 매출기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요 인사이트를 제공합니다.
- 이 보고서는 회사 개요, 재무 실적, 제품 포트폴리오, 사업 지역, 유통 전략, 주요 개발 및 전략과 같은 매개 변수를 기반으로 세계의 BRAF 키나아제 억제제 시장의 주요 기업 개요을 작성했습니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 정부 정책, 기술 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- 이 세계의 BRAF 키나아제 억제제 시장 보고서는 투자자, 제품 제조업체, 유통업체, 공급업체, 연구 및 컨설팅 회사, 신규 진입자, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 BRAF 키나아제 저해제 시장 : 약제별, 2021-2033년
제5장 세계의 BRAF 키나아제 저해제 시장 : 적응증별, 2021-2033년
제6장 세계의 BRAF 키나아제 저해제 시장 : 유통 채널별, 2021-2033년
제7장 세계의 BRAF 키나아제 저해제 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
KSA 26.06.02Braf Kinase Inhibitors Market is estimated to be valued at USD 2.12 Bn in 2026 and is expected to reach USD 3.52 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2.12 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.30% | 2033 Value Projection: | USD 3.52 Bn |
BRAF is a kinase enzyme that helps control cell growth and signalling. It may be found in a mutated (changed) form in some types of cancer, including melanoma and colorectal cancer. Blocking mutated BRAF kinase proteins may help keep cancer cells from growing. Some BRAF kinase inhibitors are used to treat cancer. About 50 % of melanomas harbors activating BRAF mutations (over 90 % V600E). BRAFV600E has been implicated in different mechanisms underlying melanomagenesis, most of which due to the deregulated activation of the downstream MEK/ERK effectors. Two compounds (vemurafenib and dabrafenib) have achieved approval by the Food and Drug Administration (FDA) for the treatment of metastatic and unresectable BRAF-mutated melanomas.
Market Dynamics
Key players in the BRAF kinase inhibitors market are focusing on obtaining patents, which is expected to create more opportunities for BRAF kinase inhibitor drugs manufacturers in the emerging economies. For instance, in September 2016, Novartis International AG secured an Indian patent for its skin cancer (melanoma) drug Tafinlar, which is used for the treatment of metastatic melanoma, the most serious and life-threatening type of skin cancer that is associated with low survival rates.
However, one of the challenges in BRAF kinase inhibitors market is patient adherence. Due to the high cost of BRAF kinase inhibitor drugs, patients are shifting from the actual treatment regime to alternatives of cancer treatments. Alternative methods available for cancer treatments is expected to hinder growth of the BRAF kinase inhibitors market in the near future. For instance, metastatic cancer requires systemic therapy or medications given through mouth or injected into the bloodstream to reach cancer cells throughout the body such as chemotherapy or hormone therapy. Other treatments may include immunotherapy, radiation therapy, surgery or a combination of these.
Key features of the study
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global BRAF kinase inhibitors market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include F. Hoffmann-La Roche AG, Novartis International AG, and Pfizer, Inc.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global BRAF kinase inhibitors market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for BRAF kinase inhibitors market, research and consulting firms, new entrants, and financial analysts.
Market Segmentation
- By Drug
- Vemurafenib
- Dabrafenib
- Lifirafenib
- Encorafenib
- By Indication
- Metastatic Melanoma
- Metastatic Lung Cancer
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Hoffmann-La Roche Ltd.
- Novartis AG
- Array BioPharma Inc. (Pfizer)
- Bayer AG
- Plexxikon Inc. (Daiichi Sankyo)
- Blueprint Medicines
- Kinnate Biopharma Inc.
- IDEAYA Biosciences
- Mirati Therapeutics
- Loxo Oncology (Eli Lilly)
- BeiGene Ltd.
- Spectrum Pharmaceuticals
- Ono Pharmaceutical
- Chugai Pharmaceutical
- BridgeBio Pharma
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug
- Market Snapshot, By Indication
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Product Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter's Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
4. Global BRAF Kinase Inhibitors Market, By Drug, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Vemurafenib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Dabrafenib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Lifirafenib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Encorafenib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
5. Global BRAF Kinase Inhibitors Market, By Indication, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Metastatic Melanoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Metastatic Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
6. Global BRAF Kinase Inhibitors Market, By Distribution Channel, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
7. Global BRAF Kinase Inhibitors Market, By Region, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Billion)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
- F. Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Array BioPharma Inc. (Pfizer)
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Plexxikon Inc. (Daiichi Sankyo)
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Blueprint Medicines
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Kinnate Biopharma Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- IDEAYA Biosciences
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Mirati Therapeutics
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Loxo Oncology (Eli Lilly)
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- BeiGene Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Spectrum Pharmaceuticals
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Ono Pharmaceutical
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Chugai Pharmaceutical
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- BridgeBio Pharma
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Analyst Views
9. Section
- References
- Research Methodology
- About Us
